196 related articles for article (PubMed ID: 37099550)
1. Full-length prion protein incorporated into prion aggregates is a marker for prion strain-specific destabilization of aggregate structure following cellular uptake.
Shoup D; Priola SA
J Biochem; 2023 Jul; 174(2):165-181. PubMed ID: 37099550
[TBL] [Abstract][Full Text] [Related]
2. The Size and Stability of Infectious Prion Aggregates Fluctuate Dynamically during Cellular Uptake and Disaggregation.
Shoup D; Priola SA
Biochemistry; 2021 Feb; 60(5):398-411. PubMed ID: 33497187
[TBL] [Abstract][Full Text] [Related]
3. A specific population of abnormal prion protein aggregates is preferentially taken up by cells and disaggregated in a strain-dependent manner.
Choi YP; Priola SA
J Virol; 2013 Nov; 87(21):11552-61. PubMed ID: 23966386
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
[TBL] [Abstract][Full Text] [Related]
5. Analyses of protease resistance and aggregation state of abnormal prion protein across the spectrum of human prions.
Saverioni D; Notari S; Capellari S; Poggiolini I; Giese A; Kretzschmar HA; Parchi P
J Biol Chem; 2013 Sep; 288(39):27972-85. PubMed ID: 23897825
[TBL] [Abstract][Full Text] [Related]
6. Uptake and degradation of protease-sensitive and -resistant forms of abnormal human prion protein aggregates by human astrocytes.
Choi YP; Head MW; Ironside JW; Priola SA
Am J Pathol; 2014 Dec; 184(12):3299-307. PubMed ID: 25280631
[TBL] [Abstract][Full Text] [Related]
7. Protease resistance of infectious prions is suppressed by removal of a single atom in the cellular prion protein.
Leske H; Hornemann S; Herrmann US; Zhu C; Dametto P; Li B; Laferriere F; Polymenidou M; Pelczar P; Reimann RR; Schwarz P; Rushing EJ; Wüthrich K; Aguzzi A
PLoS One; 2017; 12(2):e0170503. PubMed ID: 28207746
[TBL] [Abstract][Full Text] [Related]
8. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease.
Pan T; Wong P; Chang B; Li C; Li R; Kang SC; Wisniewski T; Sy MS
J Virol; 2005 Jan; 79(2):934-43. PubMed ID: 15613322
[TBL] [Abstract][Full Text] [Related]
9. A new method for the characterization of strain-specific conformational stability of protease-sensitive and protease-resistant PrPSc.
Pirisinu L; Di Bari M; Marcon S; Vaccari G; D'Agostino C; Fazzi P; Esposito E; Galeno R; Langeveld J; Agrimi U; Nonno R
PLoS One; 2010 Sep; 5(9):e12723. PubMed ID: 20856860
[TBL] [Abstract][Full Text] [Related]
10. Species barrier in prion diseases: a kinetic interpretation based on the conformational adaptation of the prion protein.
Kellershohn N; Laurent M
Biochem J; 1998 Sep; 334 ( Pt 3)(Pt 3):539-45. PubMed ID: 9729459
[TBL] [Abstract][Full Text] [Related]
11. Altered distribution, aggregation, and protease resistance of cellular prion protein following intracranial inoculation.
Ward A; Hollister JR; Choi YP; Race B; Williams K; Shoup DW; Moore RA; Priola SA
PLoS One; 2019; 14(7):e0219457. PubMed ID: 31291644
[TBL] [Abstract][Full Text] [Related]
12. Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein.
Piening N; Weber P; Giese A; Kretzschmar H
Biochem Biophys Res Commun; 2005 Jan; 326(2):339-43. PubMed ID: 15582583
[TBL] [Abstract][Full Text] [Related]
13. Non-genetic propagation of strain-specific properties of scrapie prion protein.
Bessen RA; Kocisko DA; Raymond GJ; Nandan S; Lansbury PT; Caughey B
Nature; 1995 Jun; 375(6533):698-700. PubMed ID: 7791905
[TBL] [Abstract][Full Text] [Related]
14. Protease-resistant prions selectively decrease Shadoo protein.
Watts JC; Stöhr J; Bhardwaj S; Wille H; Oehler A; Dearmond SJ; Giles K; Prusiner SB
PLoS Pathog; 2011 Nov; 7(11):e1002382. PubMed ID: 22163178
[TBL] [Abstract][Full Text] [Related]
15. Properties and pathogenicity of prion-derived peptides.
Vassallo N
Protein Pept Lett; 2009; 16(3):230-8. PubMed ID: 19275735
[TBL] [Abstract][Full Text] [Related]
16. Cofactor and glycosylation preferences for in vitro prion conversion are predominantly determined by strain conformation.
Burke CM; Walsh DJ; Mark KMK; Deleault NR; Nishina KA; Agrimi U; Di Bari MA; Supattapone S
PLoS Pathog; 2020 Apr; 16(4):e1008495. PubMed ID: 32294141
[TBL] [Abstract][Full Text] [Related]
17. Protease-resistant and detergent-insoluble prion protein is not necessarily associated with prion infectivity.
Shaked GM; Fridlander G; Meiner Z; Taraboulos A; Gabizon R
J Biol Chem; 1999 Jun; 274(25):17981-6. PubMed ID: 10364247
[TBL] [Abstract][Full Text] [Related]
18. Grp78 destabilization of infectious prions is strain-specific and modified by multiple factors including accessory chaperones and pH.
Shoup D; Priola SA
J Biol Chem; 2024 May; 300(6):107346. PubMed ID: 38718859
[TBL] [Abstract][Full Text] [Related]
19. Prion protein conversion in vitro.
Supattapone S
J Mol Med (Berl); 2004 Jun; 82(6):348-56. PubMed ID: 15014886
[TBL] [Abstract][Full Text] [Related]
20. The aminoglycoside G418 hinders de novo prion infection in cultured cells.
Arshad H; Patel Z; Mehrabian M; Bourkas MEC; Al-Azzawi ZAM; Schmitt-Ulms G; Watts JC
J Biol Chem; 2021 Sep; 297(3):101073. PubMed ID: 34390689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
